New York & Pittsburgh – November 21, 2016 – RenovaCare, Inc., (RCAR), developer of the patented CellMist™ and SkinGun™ technologies* for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced the appointment of Roger Esteban-Vives, Ph.D. as Director of Cell Sciences.
“I’m thrilled to be joining the RenovaCare team to help bring to market the company’s breakthrough stem cell spray technology, the SkinGun™,” said Dr. Roger Esteban-Vives. “What makes the SkinGun™ unique is its ability to gently spray large areas of wounds and burns with a patient’s own stem cells, within only minutes of arriving in an emergency ward. Best of all, the process is entirely natural, quick and gentle.”
RenovaCare is developing its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. RenovaCare believes the technology will be a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the U.S. alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.
Key to the RenovaCare approach is its ultra-gentle delivery of regenerative stem cells to the wound site. The company’s SkinGun™ achieves uniform distribution of fluids with 200 times greater coverage than conventional methods, according to tests conducted at Stem cell Systems GmbH (Berlin, Germany).
In addition to laboratory tests showing high distribution and concentration patterns, the SkinGun™ has also demonstrated its ability to spray powerful yet delicate skin stem cells ultra- gently, without damaging the cells. Cell viability is essential to regenerating skin for burns, wounds, and cosmetic applications.
SkinGun™ achieved impressive 97.3% cell viability after spraying, according to studies conducted by scientists at one of the world’s largest university hospitals, Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité – Universitätsmedizin Berlin.
“We’ve achieved some impressive technical results to-date. The next steps for us are to advance our breakthrough technology towards market through the regulatory and clinical studies process,” said Thomas Bold, President and CEO of RenovaCare, Inc. “I especially welcome the addition of Dr. Esteban-Vives to our team. He is one of the few scientists in the world with such deep experience in the isolation and spray of human stem cells, and we’re fortunate to have him join us.”
Among the world’s leading experts in the isolation of specific stem cells that are ideal for spraying onto burns and wounds, his research includes epidermal-dermal isolation of stem cells and investigations of post-spray dressings and their effect on freshly isolated keratinocytes.
Previously, at the McGowan Institute of Regenerative Medicine (University of Pittsburgh), Dr. Esteban-Vives worked extensively with skin stem cells, their spray application to burns, and investigation of the impact that commercially-available wound dressings have on such cells.
Dr. Esteban-Vives received his bachelor in molecular biology at the University Autonoma of Barcelona (Barcelona, Spain). He worked as a molecular biologist from 2001 through 2003 at IRTA in Cabrils, Spain.
In 2003 he joined the pharmaceutical company, Oryzon Genomics in Barcelona, Spain, and was instrumental in developing a new technology to induce and detect mutations in organisms via high-throughput molecular detection systems. From this work, he received his Ph.D. in biotechnology from the University of Barcelona.
Dr. Esteban-Vives is published in various scientific journals and lectures at national and international scientific conferences around the world. He is also an Editorial Board Member of the Journal of Acute Disease, and serves as a scientific reviewer for a myriad of scientific journals.
*RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the company’s planned or filed submissions to the U.S. Food and Drug Administration, if any, will be accepted or cleared by the FDA.
RenovaCare, Inc. is developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs, and novel medical grade liquid sprayer devices.
RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. RenovaCare is developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.
For additional information, please call Drew Danielson at: 888-398-0202 or visit:
To receive future press releases via email, please visit:
For answers to frequently asked questions, please visit our FAQ’s page:
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders, and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the company’s website and the social media channels listed below:
* This list may be updated from time to time.
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the “Company”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company’s product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Company's technologies, technical problems with the Company's research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Drew Danielson, 888-398-0202